safety of glp 1 receptor agonists GLP-1 for the Reduction Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes New MHRA warning on the

Heterogeneity and similarities in GLP-1 receptor agonist cardiovascular outcomes trials

Tirzepatide treatment was also associated with a reduction in waist circumference, systolic blood pressure, fasting insulin and plasma lipid concentrations as cardiometabolic risk parameters

Long-term dependency creates substantial financial pressure across healthcare systems

A Vively Baseline Health Check covers 60+ biomarkers, reviewed 1:1 with a registered nurse

BMJ 2024;387:e080340.ArticlePubMedPMC 24

Vadher K, Patel H, Mody R et al (2022) Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: an adjusted indirect treatment comparison